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Abstract
Intestinal dysbiosis is implicated in Systemic Lupus Erythematosus (SLE). However, the evidence of gut 
microbiome changes in SLE is limited, and the association of changed gut microbiome with the activity 
of SLE, as well as its functional relevance with SLE still remains unknown. Here, we sequenced 16S 
rRNA amplicon on fecal samples from 40 SLE patients (19 active patients, 21 remissive patients), 20 
disease controls (Rheumatoid Arthritis patients), and 22 healthy controls, and investigated the 
association of functional categories with taxonomic composition by Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PICRUSt). We demonstrated SLE patients, 
particularly those active patients, had significant dysbiosis in gut microbiota with reduced bacterial 
diversity and biased community constitutions. Among the disordered microbiota, the genera 
Streptococcus, Campylobacter, Veillonella, the species anginosus and dispar, were positively correlated 
with lupus activity, while the genus Bifidobacterium was negatively associated with disease activity. 
PICRUSt analysis showed metabolic pathways were different between SLE and healthy controls, and
also between active and remissive SLE patients. Moreover, we revealed that a random forest model 
could distinguish SLE from RA and healthy controls (AUC = 0.792), and another random forest model 
could well predict the activity of SLE patients (AUC = 0.811). In summary, SLE patients, especially the 
active patients, show an apparent dysbiosis in gut microbiota and its related metabolic pathways. Among 
the disordered microflora, 4 genera and 2 species are associated with lupus activity. Furthermore, the 
random forest models are able to diagnose SLE and predict disease activity.
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Introduction 
The gut microbe population, known as “gut microbiota” is heterogeneous and complex, and is composed 
of more than 1000 different bacterial species (1). Intestinal mucosal immunity have clarified the
correlation between the gut microbiota and the host immune system (2). Microbial abnormalities, also 
known as “dysbiosis”, is thought to be correlated with various diseases, including chronic kidney disease, 
obesity, type 2 diabetes, atherosclerosis and nonalcoholic fatty liver disease (3-6). Systemic Lupus 
Erythematosus (SLE) is a heterogenic autoimmune disease promoted by a combination of genetic and 
environmental factors that bring about an intolerance towards self-antigens (7). Although the etiology of 
SLE remains unclear, hormonal, environmental and genetic factors are thought to be of importance.
Recently, dysbiosis of the gut microbial community in the development of SLE has attracted attention. 
Multiple evidences has shown a lower Firmicutes/Bacteroidetes ratio and decreased abundance of 
some families in Firmicutes phylum may be involved in remissive SLE (8-10) However, such alterations
are also discovered in Intestinal Mucositis and Crohn’s disease (11). It was reported that the presence of 
Lactobacillus spp. in gut could attenuate kidney inflammation in lupus-prone mice in a sex 
hormone-dependent manner (12), suggesting the gut microbiome may be a possible therapeutic target 
for SLE. The association of the gut microbiome with different diseases has been shown to be diverse due 

to many factors such as host’s age, sex, genotype, diet and geography (13-16). Therefore, alterations of 
gut microbiome associated with SLE should be variable in SLE patients in Guangdong Province, China 
compared with other locations.
So far, there are limited studies on SLE and gut microbiota. Only a study observed the gut microbiota in 
active SLE patients, other studies have just focused on SLE patients in remission (8-10)(17). Whether 
the gut microbiota is associated with the disease activity still remains unclear. In this study, we 
recruited both active and remissive SLE patients to investigate the characteristic of intestinal microbes 
that are associated with disease activity. Since Rheumatoid Arthritis (RA) is another common 
autoimmune disease, we also included RA patients as the disease control to define the specificity of the 
SLE-associated gut microbiome. We found that the gut microbiota in SLE patients, especially in active 
SLE patients, had a distinct dysbiosis in microbiota and its related metabolic pathways. Six disordered 
genera and two species were revealed to be closely associated with SLE activity. Furthermore, the 
results suggested the gut microbiota were validated to have strong diagnostic potential for SLE, and
even predict the disease activity through random forest analysis. 
Materials and Methods
Research participants and sample collection 
40 SLE patients, 20 RA patients and 22 healthy controls were consecutively recruited from Nanfang 
Hospital, Southern Medical University during 2017. All SLE and RA patients fulfill the American 
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College of Rheumatology (ACR) classification criteria for SLE or RA disease (18-20). All patients with 
acute intercurrent illnesses or infections and those who used probiotics or antibiotics within 1 month 
before admission were excluded(6). The gender- and age-matched healthy controls (HC) who had no 
known history of autoimmune diseases were also recruited from the Health Examination Centre of 
Nanfang Hospital. All the participants were female. Average age of SLE, RA and HC group was 37.46 ± 
14.17, 44.00 ± 6.53, and 37.18 ± 14.67 respectively (P = 0.142). 
Based on the systemic lupus erythematosus disease activity index (SLEDAI) (21), all the SLE 
patients were divided into the active SLE patients (A) (SLEDAI ≥ 8) (n = 19) and remissive SLE 
patients (R) (SLEDAI < 8) (n = 21). Exception of the age and gender distribution, patients in group A
showed many significant differences from that of group R, having more severe symptoms, including 
anemia, hypocomplementemia, impaired renal functions and increased autoantibodies, all of which are
consistent with the clinical characteristics of SLE (Table 1).
For all participants, the fresh fecal samples were frozen at -80 °C immediately after collection. 
Ethics approval was granted by the Ethics Committee of Nanfang Hospital, and all of the methods used 
were in accordance with the approved guidelines. Written informed consent was required from all 
patients and healthy volunteers in the study. 
Illumina Miseq sequencing of 16S rRNA gene-based amplicons and data processing 




med Bio Medicai., LTD., Guangdong, China) following the manufacturer’s instructions. All the 
individually processed human fecal DNA extractions were amplified by polymerase chain reaction 
(PCR). The forward primer (5’-ACT CCT ACG GGA GGC AGC AG-3’) and reverse primer (5’-GGA 
CTA CHV GGG TWT CTA AT-3’) were used to amplify the 16S rRNA gene V3-V4 variable region 
from the bacteria by polymerase chain reaction (PCR) as described previously (22). Briefly, 
amplifications were performed using a step cycling protocol consisting of 98 °C for 30 s, 35 cycles of 
98 °C for 10 s, 54 °C for 30 s, and 72 °C for 45 s, ended with the final elongation at 72 °C for 10 min. 
PCR products were purified using an AxyPrep PCR Cleanup Kit (Axygen, California, USA).  
For the sequencing of 16S rRNA gene-based amplicons, the amplicon library was prepared using a 
TruSeq Nano DNA LT Library Prep Kit (Illumina Inc, CA, USA). The sequencing reaction was 
conducted using Illumina MiSeq platforms and the data were analyzed by the Quantitative Insights Into 
Microbial Ecology platform (QIIME, www.qiime.org) using the default parameters (23). The raw 
sequence data for 16S rRNA gene sequencing data sets was available from the Sequence ReadArchive 
(SRA) database (http://www.ncbi.nlm.nih.gov/sra) at accession number PRJNA493726. 
Before assembly, sequence reads were first filtered to remove low-quality or ambiguous reads, 
including reads lacking exact matching with the primer, sequences with mismatch ratio sequences higher 
than 0.05 in the overlap region and raw reads shorter than 100 bp with Trimmomatic v.0.32 software 
(24). Paired-end clean reads were merged using FLASH (25) according to the relationship of the overlap 




opposite end of the same DNA fragment, the maximum allowable error ratio of an overlap region of 0.2, 
and the spliced sequences were called raw tags.  
High-quality Sequences with a distance-based similarity of 97% or greater were grouped into 
operational taxonomic units (OTUs) using the Vsearch algorithm. Representative sequence was then 
extracted from each OTU. Next, the chimeric sequences were detected and removed. To assign 
taxonomy information to each clustered feature, extracted representative sequences were subjected to 
similarity search against Greengenes sequence and taxonomy database using RDP classifier algorithm 
(ucluster approach with default settings) and the classify-sklearn plugin within Qiime software (version 
1.9.1). The phylogenetic relationships were determined based on a representative sequence alignment 
using Fast-Tree (26). Computation of α-diversity metrics and β-diversity metrics were performed on all 
samples within the feature table with Qiime diversity alpha/beta plugin. Rarefaction curve plots the 
number of individual’s sample versus the number of species, which was done with Qiime diversity 
alpha-rarefaction plugin. Rank abundance curve portray relative abundance and species diversity within 
a community by plotting relative abundance of species (y-axis) against their rank in abundance (x-axis), 
which plotted using QIIME v.1.9.1 software.  
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) is a 
bioinformatics software package designed to predict metagenome functional content from marker gene 
surveys and full genomes. PICRUSt analysis was performed to identify Kyoto Encyclopedia of Genes 




taxonomic composition (27). 
Comparisons of relative abundance of taxa between groups were performed using Linear 
discriminant analysis Effect Size (LEfSe), a non-parametric Mann-Whitney U test applied to detect 
features with significant differential abundance with respect to the groups compared, followed by a 
Linear Discriminant Analysis (LDA) to estimate the effect size of each differentially abundant feature in 
Linux platform (28). 
 
Statistical analyses 
We used the mean (±SD) to express measurement data that obeyed a normal distribution, the median 
(interquartile range) to express measurement data that obeyed a skewed distribution, and a percentage to 
express enumeration data. Mann-Whitney U test or Student t test was performed to compare the 
variables of 2 sample groups. Multiple group comparisons were made by the Kruskal-Wallis test or 
one-way analysis of variance. False discovery rate (FDR) correction for multiple comparisons was 
employed, and the statistical power was analyzed via power and sample size calculation in R 
software (29, 30), then the False Discovery Rate q-value was calculated. 
 The α-diversity determines the species richness and evenness within bacterial populations. The 
α-diversity metrics include: Observed species and Chao1 (microbial richness), and Shannon index and 
Simpson index (microbial diversity) (31). The β-diversity determines the shared diversity between 




UniFrac distances measure the shared phylogenetic diversity between communities. A smaller UniFrac 
distance between two samples indicates a higher similarity among the two microbial communities (32). 
Principal coordinates analysis (PCoA) was plotted using the package in R software (Version 3.4.4). The 
Wilcoxon rank sum test was used to determine significance in α-diversity and β-diversity.  
We used spearman algorithm to analyze the relationship among microbiota, predicted pathways and 
SLE activity index. The Random Forest models were trained by “randomForest” package with default 
parameters in R, then the performance of the model was assessed with a ten-fold cross-validation 
approach and measured by area under the receiver-operating characteristic (ROC) (33). All tests were 
performed using GraphPad Prism (v6.0) (GraphPad Software, Inc., CA, USA), SPSS Statistics 
(V.24.0.0.0) (SPSS Inc., Chicago, USA) or R software (Version 3.4.4).  
 
Results 
Characteristics of 16S rRNA sequences.  
A total of 82 samples were subjected to 16S rRNA sequencing. These samples were composed of three 
groups including 22 healthy individuals, 20 RA patients and 40 SLE patients. We obtained 2182143 16S 
rRNA sequencing reads from stool samples of SLE patients, 976140 reads from RA patients and 
1277858 reads from HC, which belong to 714 kinds of operational taxonomic unit (OTUs). The 
parameters, including Chao1 rarefaction curves, Shannon rarefaction curve, and rank abundance of 





Difference of the gut microbiota in SLE patients from those of controls  
 The α-diversity between two groups was compared using Chao1, Observed species, Shannon index and 
Simpson diversity indices. Overall, the α-diversity metrics Chao1 and Observed species were 
significantly higher in healthy controls than in SLE patients (P = 0.038; P = 0.004, respectively), 
indicating that the gut microbiome in SLE patients exhibited a lower richness than healthy controls 
(Figure 1A and B and Supplementary Table S1). However, no difference in Shannon and Simpson index 
(P = 0.089; P = 0.092, respectively) was observed between SLE patients and healthy individuals, 
suggesting that the evenness of the gut microbiome of the two groups had no significant difference 
(Supplementary Table S1). There were no associations between α-diversity and drug treatments, such as 
Hydroxychloroquine, Glucocorticoid, Cyclophosphamide, and Biological agent (Supplementary Figure 
S2).  
To measure the extent of the similarity of fecal microbial communities, β-diversity was calculated 
using unifrac distances. Principal coordinate analysis (PCoA) based on weighted and unweighted 
UniFrac distance matrix were used for visualizing sample relationships, and ADONIS analysis was used 
to test the homogeneity of dispersion among different groups. Our results suggested that there were no 
associations between β-diversity and medicine treatments, including Hydroxychloroquine, 
Glucocorticoid, Cyclophosphamide, and Biological agent (Supplementary Table S2 and Figure S3), 




structure of microbiota of SLE patients differed from healthy controls (ADONIS analysis, P < 0.001, R2 
= 0.054) (Figure 1C and Supplementary Table S3). Thus, the microbial diversity was significantly 
different between SLE group and healthy controls. 
We then analyzed the phylum-level profiles of feces between SLE patients and healthy controls. The 
phylum level profiles for gut microbiota of SLE patients and controls were fairly similar, except for 
reads from the phyla Fusobacteria (P = 0.027) and Tenericutes (P = 0.002) (Figure 1D-F).  A lower 
Firmicutes / Bacteroidetes (F/B) ratio was reported in the feces of remissive SLE patients compared to 
healthy controls (34). However, we showed the ratio of F/B the feces of SLE had a decreasing trend but 
no significant difference compared with HC group (Supplementary Table S4). 
To further determine the phylogenetic clustering pattern between these two groups, the logarithm 
linear discriminant analysis (LDA) was performed (Figure 2). The phylum Tenericutes, along with 
Mollicutes and RF39, were significantly reduced in the intestinal flora of SLE patients compared with 
healthy controls. In addition, patients with SLE exhibited a significant decrease in the genus 
Faecalibacterium alongside its species prausnitzii, while the taxonomic clade Cryptophyta and genus 
Roseburia were reduced in the gut microbiota of SLE group. On the contrary, the taxonomic clade 
Bacilli from the phylum Firmicutes showed clustered differences, while Streptococcaceae and 
Lactobacillaceae were expanded in the feces of SLE patients compared with healthy controls. Moreover, 
the genera Streptococcus and Lactobacillus, along with their species Streptococcus. anginosus and 




addition, the feces of SLE patients showed an increase in genus Megasphaera (significant taxa [p<0.005, 
Kruskal–Wallis test] with LDA score >2 were shown). Taken together, sequence profiling of the gut 
microbiota revealed an apparent dysbiosis of the gut microbiota in SLE patients, which was 
characterized by reduced bacterial α-diversity and biased community constitutions. These results 
demonstrated the gut microbiota of patients with SLE differed from those of healthy controls. 
To investigate whether the disordered intestinal microbes were specific to SLE patients, we further 
compared the intestinal microflora distribution between SLE and RA patients. There were no significant 
difference in α-diversity (Supplementary Table S1) and β-diversity (Supplementary Table S3 and Figure 
S4C-D) between two groups.  LEfSeanalysis showed the different microbiota between SLE group and 
RA group (Supplementary Figure S4). The taxonomic clade EB1017, Ellin6529, and Anaerofilum were 
increased in the intestinal flora of RA patients, while the Lactobacillales from the Bacilli, with its genus 
Streptococcus were enriched in the feces of SLE patients compared with RA patients. In addition, the 
phylum Fusobacteria, along with its taxonomic clade Fusobacteriia, Fusobacteriales, Fusobacteriaceae, 
and Fusobacterium were increased in the feces of SLE patients. The genus Megasphaera and Veillonella, 
with its species Veillonella. dispar, were also enriched in the feces of SLE group compared with RA 
group (significant taxa [p<0.05, Kruskal–Wallis test] with LDA score >2.5 were shown).  
Collectively, these results demonstrated that the gut microbiota of SLE patients differed from 
healthy individuals, however, there was no significant difference in gut microflora diversities between 




feces of SLE patients compared with healthy controls and RA patients.  
 
Difference of microbiota profiling in active SLE patients from remissive SLE patients.  
Given that the gut microbiota was significantly different between SLE patients and healthy controls, we 
next investigated whether the gut microbiota was associated with disease activity of SLE. Firstly, we 
compared 16S rRNA sequences of A group (active SLE patients) with R group (remissive SLE patients). 
The unweighted UniFrac distance analysis of β-diversity difference demonstrated that the structure of 
the microbiota of A group differed from R group (ADONIS analysis, P =0.047, R2 = 0.039) (Figure 3A 
and Supplementary Table S3), while no obvious difference was observed in α-diversity (Supplementary 
Table S1), suggesting that the community constitutions in A group were distinctly different from R 
group, but no difference was found in microbial diversity. 
As shown in Figure 3, LEfSe analysis further demonstrated that Actinomycetales and 
Bifidobacteriales from phylum Actinobacteria showed clustered differences, and the genus 
Bifidobacterium was increased in the feces of remissive SLE patients compared with active SLE patients. 
In addition, the species Ruminococcus. gnavus was reduced in the feces of active SLE patients, whereas 
Lactobacillales from the Bacilli, along with its genus Streptococcus and species Streptococcus. 
anginosus, were enriched in the feces of A group compared with R group. Moreover, the genus 
Oribacterium was increased in the intestinal flora of active SLE patients. Furthermore, active SLE 




Proteobacteria, along with its Campylobacterales and Campylobacter (significant taxa [p<0.005, 
Kruskal–Wallis test] with LDA score >2 were shown). Finally, the ratio of F/B in remissive SLE patient 
group had a decreasing trend but no significant difference compared with HC group (Supplementary 
Table S4). Altogether, these results indicated that the gut microbiota profiling of active SLE patients 
were markedly different from that of remissive SLE patients.  
 
Aberrant microbiome-associated pathway is correlated with the activity of SLE 
patients.  
Another emphasis of our study was to disclose the functional variation in the SLE gut microbiota 
community. Therefore, we predicted the microbiota-derived pathways using the PICRUSt algorithm 
with the KEGG database and compared functional abundances among the SLE, RA, and HC groups. In 
total, we characterized six different pathway categories between SLE group and HC group (Figure 4). 
The pathways of Apoptosis and Purine metabolism were significantly increased in SLE patient group 
compared with HC group (Figure 4A), while four pathways, including Pathways in cancer, Bacterial 
chemotaxis, Bacterial motility proteins, and Flagellar assembly, were decreased in SLE patients (Figure 
4B). In addition, nine different functional pathways were identified between A group and R group 
(Figure 5). Five were related to Synthesis and degradation of ketone bodies, Apoptosis, Lipid 
metabolism, Secretion system, and Staphylococcus aureus infection, which were significantly higher in 




metabolism, Carbohydrate metabolism, Primary bile acid biosynthesis, and Secondary bile acid 
biosynthesis, were obviously increased in remissive SLE patients compared with active patients (Figure 
5B). However, there was no different pathway between SLE and RA group (date not shown). 
We further examined correlations among SLE/HC-associated taxa and disordered functional 
pathway to obtain an overview of how specific taxa act during metabolic dysfunction in patient gut. For 
SLE patients, we characterized a positive correlation between the enrichment of Streptococcus and 
increased Apoptosis pathway (r = 0.807, P < 0.000, FDR < 0.000) and a negative correlation between 
Streptococcus and Pathways in cancer (r = -0.550, P < 0.000, FDR < 0.000) (Figure 6A). Further 
analysis also revealed the active SLE patient-enriched genus Streptococcus was negatively associated 
with pathways of Alanine aspartate and glutamate metabolism, Primary and secondary bile acid 
biosynthesis (r = -0.680; r = -0.437; r = -0.434, P < 0.01, FDR < 0.05, respectively) (Figure 6B), but 
positively associated with five increased pathways, including Synthesis and degradation of ketone 
bodies, Apoptosis, Lipid metabolism, Secretion system, and Staphylococcus aureus infection (r = 0.574; 
r = 0.829; r = 0.406; r = 0.486; r = 0.903, P < 0.01, FDR < 0.05, respectively) (Figure 6C).  
Thus, several aberrant microbiome-associated gut metabolic pathways were associated with SLE 
using PICRUSt analysis. Interestingly, the SLE-enriched genus Streptococcus was positively associated 
with the pathways of Apoptosis, the metabolism of lipid, amino acid and bile acid, Secretion system, and 





Association of disordered microbiota and aberrant microbiome-associated pathway 
with activity of SLE.  
SLEDAI, Complement C3, C reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR) and 
anti-double stranded DNA (anti-dsDNA) were commonly used to indicate the disease activity of SLE 
patients (21, 35, 36). 
 At genus and species levels, Lactobacillus, Streptococcus, Megasphaera, Fusobacterium, 
Veillonella, Lactobacillus. mucosa, Streptococcus. anginosus, and Veillonella. dispar were increased in 
the feces of SLE patients compared with healthy controls or RA patients. Meanwhile, Streptococcus, 
Oribacterium, Campylobacter, and Streptococcus. anginosus were enriched, but Bifidobacterium and 
Ruminococcus. gnavus were reduced in the gut microbiota of active SLE patients compared with that of 
remissive SLE patients. Except Bifidobacterium, five changed genera were positively associated with 
disease activity (Figure 7A-F and Supplementary Table S5). For example, the abundance of 
Streptococcus was positively correlated to SLEDAI (r = 0.492, FDR q = 0.008), while negatively 
associated with Complement C3 (r = -0.502, FDR q = 0.008) (Figure 7A). Campylobacter and 
Streptococcus. anginosus also showed a positive correlation with SLEDAI (r = 0.470, FDR q = 0.009; r 
= 0.388, FDR q = 0.040, respectively) (Figure 7). Moreover, the abundance of Veillonella and its species 
Veillonella. dispar showed negative correlations with Complement C3 (r = -0.475, FDR q = 0.008) 
(Figure 7).  




eight aberrant microbiome-associated pathways (Figure 6). We further explored whether these eight 
disordered pathways were also related to the activity of SLE (Supplementary Table S5). Alanine 
aspartate and glutamate metabolism, Secondary bile acid biosynthesis, and Lipid metabolism were 
closely associated with SLEDAI (r = -0.376; r = -0.382; r = 0.318, FDR q <0.001, respectively) (Figure 
7G-I).  As such we hypothesized that the genus Streptococcus might play an important role in the 
disease progression of SLE through these three pathways. 

Potentials of gut microbiota for SLE diagnosis or disease activity monitoring  
Given that the gut microbiota in SLE patients, especially in active SLE patients, had a distinct dysbiosis 
in microbiota, we next addressed the potential diagnostic value of the gut microbiota as potential 
biomarkers for SLE by ROC curve analyses. Due to its non-parametric assumptions, random forest was 
used to detect linear and nonlinear effects and potential taxon–taxon interactions, to identify taxa that 
could differentiate SLE subjects from control subjects (healthy controls and RA patients), and to 
discriminate active SLE patients from remissive patients. We used 10-fold cross-validation approach to 
evaluate the performance of model, and predictive power was scored in ROC analysis. We first made the 
mode to differentiate the SLE patients from healthy controls and RA patients based on the genus and 
species levels. We showed that the area under the curve (AUC) was 0.792 (95% CI: 0.750−0.835) 
(Supplementary Table S6 and Figure 8A), suggesting that the gut microbiota had the potential to 




top 10 genera and species, 8 belonged to the phylum Firmicutes, 1 belonged to Fusobacteria, and 1 
belonged to Actinobacteria. Of the 8 genera in the Firmicutes phylum, 5 were part of Clostridia class, 
and 3 were Bacilli (Supplementary Table S6). Furthermore, among the 10 genera and species, the 
mucosa, Lactobacillus, Megasphaera, and Streptococcus were significantly enriched, while 
Faecalibacterium was decreased in the feces of SLE patients compared with healthy controls. In 
addition, both Veillonella and Fusobacterium were increased in the gut microbiota of SLE patients than 
RA patients (Figure 2; Supplementary Figure S4 and Table S5). Accordingly, most of the genera and 
species in the model were the disordered genera in the feces of SLE group compared with healthy 
controls and RA patients. 
 We further built another model to distinguish active SLE patients from remissive patients based on 
the genus and species levels. In this model, the AUC was 0.811 (95% CI: 0.754-0.869) (Supplementary 
Table S7 and Figure 8B), suggesting that the gut microbiota had the potential to monitor the activity of 
SLE. Anti-dsDNA was reported to be reasonably sensitive and specific in the diagnosis of SLE, and 
raised titers of anti-dsDNA along with hypocomplementemia were associated with the activity of 
SLE(37). We showed that the AUC value for combination of Complement C3 and anti-dsDNA was only 
0.773 (95% CI: 0.597–0.949) (Supplementary Figure S6). These results indicated that the combination 
of the gut microbiota might have a better surveillance value for SLE activity than the combination of 
Complement C3 and anti-dsDNA. Morever, as shown in the model, out of the top 10 genera and species, 




Among the 5 genera in the Firmicutes phylum, 3 were from the Clostridia class, 1 was Erysipelotrichi 
and 1 was Bacilli (Supplementary Table S7). In this case, the Campylobacter, Streptococcus, and 
Oribacterium were enriched, while the gnavus and Bifidobacterium were reduced in active SLE patients 
compared with remissive SLE patients (Figure 3 and Supplementary Table S7). Altogether, a great part 
of the genera and species in the model were disordered genera in the feces of active SLE patients, 




SLE is an autoimmune disease that affects multiple tissues,  and causes joint pain, renal disease, muscle 
pain, fever, poor circulation, inflammation, fatigue, loss of appetite and other symptoms (38). Though 
the cause of SLE still remains unclear, it is thought to be involved with hormonal, genetic and 
environmental factors (39). The gut microbiome was believed to be a key factor in influencing 
predisposition to autoimmunity diseases (40). Recent studies further supported that gut microbiome 
dysbiosis could act as an important factor in promoting chronic inflammation into autoimmune diseases 
(2, 41, 42). However, there were only limited works in exploring the potential relationship of gut 
microbiome with SLE (8-10, 17, 39). In this study, we have provided new evidence about the gut 
microbiome dysbiosis in female SLE patients by fecal bacteria sequencing.  Importantly, we for the 




We investigated the profiling of the gut microbiota and showed a distinct dysbiosis of the gut 
microbiota in SLE patients, which was characterized by reduced bacterial α-diversity and biased 
community constitutions. Most of the patients in our study were currently on various 
immunosuppressants and glucocorticoids treatments. Veena Taneja et al. have demonstrated that RA 
patients using methotrexate (MTX) and hydroxychloroquine exhibited an increase in species richness 
and diversity (43). However, our results showed no significant relationship between drug treatments and 
the abundance diversity of gut microbiota in the SLE patients, which might because the most of enrolled 
patients were treated with steroids or immunosuppressants, while only 4 patients did not use any drugs. 
 Phyla Firmicutes together with Bacteroidetes usually account for more than 90% of all 
phylogenetic species, were involved in host metabolism and immunity (44). In our study, the Phyla 
Firmicutes and Bacteroidetes occupied the most abundant microorganism, consistent with the typical 
human intestinal microbiome structures. It was reported that the Firmicutes / Bacteroidetes ratio was 
significantly lower in the feces of SLE patients in remission (8). However, no significant different for 
our cohort of remissive SLE patients and healthy controls (P > 0.05). Also, there was no significant 
difference in the Firmicutes / Bacteroidetes ratio between active SLE and healthy controls (P > 0.05), 
consistent with the available data (17). The changes of the genera in SLE patients of our study were only 
partly consistent with previous studies (8, 10, 17, 45), which might partially due to the sample size and 
geographical locations of patients. It is well known that cohorts with different patient characteristics, 




profiling (15, 16, 46-48). Therefore, the alterations of gut microbiome associated with SLE should 
display differences among different geographical locations and disease status. 
In this study, we found that the abundance of pathogenic genus Streptococcus, with its species 
anginosus, and genus Megasphaera were significantly enriched in the feces of SLE patients compared 
with healthy controls; genus Streptococcus and its species anginosus were positively correlated to the 
activity of SLE. In addition, the genus Veillonella and its species dispar were significantly increased in 
the gut microbiota of SLE patients compared with RA patients and had a positive association with the 
activity of SLE. The association of these disordered genera with the activity of SLE was most striking, 
and to our knowledge, this is the first study to describe such a significant relationship with SLE. The 
genera Streptococcus and Megasphaera were reported to be closely related to the intestinal disturbance 
of autoimmune disorders. For example, Streptococcus and Megasphaera were enriched in primary 
biliary cirrhosis (49) and Pediatric Autoimmune Neuropsychiatric Disorders (50).  Also, Streptococcus 
was relatively increased in RA patients (43).  It was demonstrated that S. anginosus rarely caused 
infections in healthy individuals, but caused infections in the immunodeficient individuals(51). As 
reported, genera Streptococcus and Veillonella had pro-inflammatory effects. For example, the 
combination of Streptococci with Veillonella appeared to negate IL-12p70 production, while augment 
IL-8, IL-6, IL-10, and tumor necrosis factor alpha (TNF-α) response (52). 
  The SLE patients, especially the active patients, had an increased population of oral bacteria, 




microbiome of liver cirrhosis, colorectal cancer, RA, and ACVD patients also showed an increase in the 
abundance of oral bacteria in gut microbiota (53), and only RA and ACVD have been epidemiologically 
associated with periodontitis. Interestingly, our results suggested that the abundance of genus 
Streptococcus were enriched in active SLE patients, suggesting that the oral microbiota might be 
overrepresented in the lower gastrointestinal populations of patients with active SLE. Besides, more 
severe forms of periodontitis were found in SLE subjects that had higher bacterial loads (54), resulting 
in an increase in oral bacteria entering the intestine. 
 Furthermore, our data showed that many beneficial commensal microbes, such as Roseburia, 
Faecalibacterium and its species prausnitzii were depleted in SLE patients. Meanwhile, the genus 
Bifidobacterium was adversely correlated with activity of SLE. These microbes belongs to the 
phylofunctional core of the intestinal  microbiota (55, 56) , which can produce short chain fatty acids 
(SCFAs), especially butyrate-acid, to play multiple critical roles in the maintenance of human health, 
including producing energy components and intestinal epithelial nutrition (57), reducing the severity of 
inflammation (58), maintaining intestinal barrier functions (59) and enhancing colon motility functions 
(60).  
 Moreover, we observed an increased abundance of beneficial commensal genus Lactobacillus 
and its species Lactobacillus mucosae in the feces of SLE cohort compared to healthy controls. 
Supportive of a role for Lactobacilli in the pathogenesis of lupus, taxa in this genus were found to be 




associated with more severe disease, whereas they were reduced as disease is controlled with 
dexamethasone (17). As reported (61)Lactobacillus. reuteri increased over time in the feces of mice 
from both lupus models as their disease progress, in addition, Lactobacillus spp. were increased in a 
longitudinal cohort of SLE patients compared with healthy controls. In this study, the 
pDC/IFN-promoting properties of L. reuteri in the context of a lupus-prone host suggest a paradigm in 
which a bacterium that is normally considered a probiotic may become harmful under certain genetic or 
environmental conditions. We also observed that Lactobacillus were enriched in feces of SLE patients, 
suggesting a potential role for these taxa in SLE pathogenesis, which need further research in the future. 
 Our study has demonstrated that some pro-inflammatory bacteria in genera Streptococcus, and 
Campylobacter expanded, while some anti-inflammatory bacteria in genera Roseburia, 
Faecalibacterium, and Bifidobacterium reduced in the feces of SLE patients, especially the active 
patients, resulting in the release of inflammatory factors, then aggravating the systemic inflammation 
level. Some pro-inflammatory pathogens increased accompanied with the intestinal mucosal barrier 
compromised, which lead to more bacterial LPS transferring into lymph nodes and blood to stimulate 
the TOLL-like pathway of the host cells, and produce inflammatory cytokine (62). SLE patients 
generally used massive immunosuppressive agents and glucocorticoids during the active period, which 
could inhibit the immune system and might cause a large increase in opportunistic pathogens (63, 64). 




consequence of SLE. However, to posit further on this, is beyond the scope of this study, and we will 
focus on this in the future research.  
 In addition, several aberrant microbiome–associated gut metabolic pathways were revealed to be 
associated with SLE using PICRUSt analysis. We found that SLE patients were enriched in multiple 
metabolic pathways containing gene functions of Apoptosis, Purine metabolism, and the Apoptosis were 
positively associated with the genus Streptococcus that was highly enriched in SLE patients and 
especially in active patients. As reported, Apoptosis pathway played an important role in the 
pathogenesis of SLE (65). Besides, among these altered pathways, the alanine, aspartate and glutamate 
metabolism, Secondary bile acid biosynthesis, and Lipid metabolism were not only related to the disease 
activity, but also significantly associated with Streptococcus. The alanine, aspartate and glutamate 
metabolism, which was identified to be increased in remissive SLE patients in our study, had been 
previously reported to play a pivotal role in resting or activated T cells (66). Lipid metabolism 
participates in the regulation of many cellular processes such as cell growth, proliferation, differentiation, 
survival, apoptosis, inflammation, motility, etc (67). In active SLE patients, the dyslipidemia was more 
prevalent, suggesting that inflammation may be related to lipid metabolism (68). Thus, Streptococcus 
might play an important role in the pathogenesis of SLE through these pathways.  
Due to the heterogeneous presentation of SLE patients and their unpredictable disease course, there 
is a great need for accurate assessment of disease activity. Several immunologic markers including 




monitoring of disease activity, however, these traditional biomarkers are better related to certain clinical 
manifestations of the disease, especially nephritis, rather than to the activity of the disease itself (69). 
Currently, disease activity in SLE can be assessed using composite disease activity indices, such as 
SLEDAI score and British Isles Lupus Assessment Group (BILAG) score (70). However, the composite 
disease activity indices depend on differential organ involvement and physical assessments (71, 72). 
Besides, they could be complex for use in routine clinical practice. Thus, there is a great urgent for the 
identification of new biomarkers that can quantify disease activity (73, 74).  
Moreover, due to the existence of a remarkable difference in microbiota between SLE status, the 
random forest models were built in this study to examine whether microbiota composition could identify 
their disease status. Of note, a random forests model was identified for diagnosing SLE from healthy 
controls and RA patients with a AUC value of 0.792. To be mentioned, another random forest predictive 
model showed to be a suitable model for the prediction of disease activity of SLE with the AUC of 0.811, 
which was higher than the combination of Complement C3 and anti-dsDNA (AUC=0.773). Accordingly, 
our results suggested that the gut microbiota might be potential biomarkers for diagnosis of SLE and 
even monitoring SLE activity in a non-invasive method.  However, the sample size enrolled in our 
study was relatively small, therefore, more samples are needed to evaluate the performance of the 
disordered genera in the future. 
In summary, these disordered bacteria and related metabolic pathways might provide clues in 




monitoring SLE activity in a non-invasive method. Specific microbial clades might be viable targets for 
the therapeutic manipulation by dietary interventions, prebiotics, probiotics and specifically tailored 
antibiotics. Determining the functions of the microbial clades that expand or contract in SLE will 
contribute to developing effective strategies to target them. However, the key role of microbiota in SLE 
pathogenesis and prospective mechanistic studies still need to be further investigated. 
 
Conclusions 
In this study, we reveal that intestinal dysbiosis and aberrant metabolism pathways are existed in SLE 
patients, especially in active SLE patients. Notably, there are 4 disordered genera and 2 species that are 
associated with the clinical disease activity in our patient cohort. Furthermore, there are two kinds of 
genera-panels can be the indicators for diagnosing or monitoring disease activity of SLE by random 
forest algorithm. However, we also recognize the limitations of our study. Since the results are deduced 
by a single-center study with a relatively small sample size, larger and prospective cohort studies will be 
required to verify and validate this predictive model. 
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Table 1: Characteristics of the active SLE patients and remissive SLE patients.  
 A (n = 19) R (n = 21) P-value 
Age, years 34.05 (13.92)  40.57 (13.63) 0.143 
WBC, 109/L # 7.40 (5.32-8.53) 6.72 (5.72-8.22) 0.955 
RBC, 1012/L # 4.17 (3.49-4.35) 4.33 (4.00-4.58) 0.0389* 
HGB, g/L # 106 (95-117.50) 126 (115-133.25) < 0.001 *** 
PLT, 109/L# 205 (152.50-308.00) 235.50 (202.25-272.50) 0.558 
C3, g/L 0.68 (0.32) 0.93 (0.23) 0.0013** 
CRP, mg/L # 1.68 (0.65-4.66) 1.56 (0.57-4.07) 0.765 
ESR, mm/h # 21.50 (11-53.50) 19.00 (5.00-60.00) 0.457 
Pyuria, n (%) 
- (negative) 6 (31.58) 17 (80.95) 
0.002** 
+ (positive) 13 (68.42) 4 (19.05) 
Albuminuria᧨n (%) 
- (negative) 3 (15.79) 15 (71.43) 
0.000*** 
+ (positive) 16 (84.21) 6 (28.57) 
Hematuria᧨n (%) 
- (negative) 4 (21.05) 19 (90.48) 
0.000*** 
+ (positive) 15 (78.95) 2 (9.52) 
24-UTP, mg/24h # 0.68 (0.22-2.29) 0.17 (0.11-0.46) 0.048* 
Anti-dsDNA, UI/ml # 65.64 (16.24–156.66) 20.07 (2.88–62.20) 0.0186* 
Lupus nephritis, n (%) 15 (78.95) 9 (42.86) 0.20 
SLEDAI#  12 (9.5-14.0)  4 (1.5-6.0) < 0.001 *** 
Medication use 
Hydroxychloroquine 12 10 0.119 
Glucocorticoid 17 16 0.527 
Cyclophosphamide 3 3 0.574 




A, the active SLE patients; R, the remissive SLE patients; WBC, white blood cell; RBC, red blood cell; 
HGB, haemoglobin; PLT, platelet; C3, Complement component 3; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; 24-UTP, 24-hour urine protein; Anti-dsDNA, anti-double stranded DNA; 
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. Data represent the mean (standard 
deviation), and the data # represents the median (interquartile range). The P values were calculated by 





Figure 1. The different microbial diversity between SLE patient group and healthy controls. A-B. 
Significantly different richness of α-diversity between the gut microbiota of SLE and HC. C. Principal 
coordinate analysis illustrating the grouping patterns of SLE and HC group based on the unweighted 
UniFrac distances. Each closed circle represented a sample. Distances between any pair of samples 
represented their dissimilarities. D. The average relative abundances of the predominant bacterial taxa at 
the phylum level in the SLE patients and HC group. E-F. The significantly different phyla in SLE 






Figure 2. The differentially abundant taxa between the feces of SLE patients and healthy controls. 
LEfSe analysis was performed to identify differentially abundant taxa, which are highlighted by the 
phylogenetic tree in cladogram format (A) and the LDA scores (B). Green color indicates an increase 
taxa in the feces of SLE compared with HC, while the red color indicates an increase taxa in the feces of 
HC compared with SLE (significant taxa [p<0.005, Kruskal–Wallis test] with LDA score >2 were 
shown). SLE, Systemic lupus erythematosus patients; HC, healthy controls.  
 
Figure 3. The different microbial diversity between the feces of active SLE patients and remissive SLE 
patients. A. Principal coordinate analysis illustrating the grouping patterns of the feces of A group and R 
group based on the unweighted UniFrac distances. Each closed circle represented a sample. Distances 
between any pair of samples represented their dissimilarities. B. The significantly different phyla in the 
feces of A group compared with R group. C-D. LEfSe analysis was performed to identify differentially 
abundant taxa, which are highlighted by by the phylogenetic tree in cladogram format (C) and the LDA 
scores (D). Significantly discriminative taxa among the active patients (red), remissive patients (blue) 
and healthy controls (green) were determined using Linear Discriminant Analysis Effect Size (LEfSe) 
(significant taxa [p<0.005, Kruskal–Wallis test] with LDA score >2 were shown). A, the active SLE 





Figure 4. The significantly different predicted metabolic pathways between SLE patients and healthy 
controls. A. Significantly two predicted metabolic pathways were increased in SLE compared with 
healthy controls. B. Four predicted metabolic pathways were decreased in SLE patient group compared 
with healthy controls. It was analyzed by Kruskal–Wallis, and the False Discovery Rate (FDR) q-value 
was then calculated, and q-values <0.1 was considered significant. SLE, Systemic lupus erythematosus 
patients; HC, healthy controls. 
 
Figure 5. The significantly different predicted metabolic pathways between active SLE patients and 
remissive SLE patients. A. Significantly five predicted metabolic pathways were increased in active 
SLE compared with remissive SLE patients. B. Four predicted metabolic pathways were enriched in 
remissive SLE patients compared with active SLE patients. A, the active SLE patient group; R, the 
remissive SLE patient group. It was analyzed by Kruskal–Wallis, and the False Discovery Rate (FDR) 
q-value was then calculated, and q-values <0.1 was considered significant. 
 
Figure 6. The associations between the abundance of genus Streptococcus and disordered metabolic 
pathways. A. The predicted metabolic pathway Apoptosis and Pathways in cancer were correlated with 
SLE-enriched genus Streptococcus. B. The predicted metabolic pathway of Alanine aspartate and 




negatively associated with active SLE-enriched genus Streptococcus. C. Five pathway categories, which 
were higher in active SLE patients compared to remissive SLE patient group, were positively associated 
with active SLE-enriched genus Streptococcus. They were analyzed by Spearman ranks tests, and the 
False Discovery Rate (FDR) was calculated for multiple testing. SLE, Systemic lupus erythematosus 
patients; FDR, the False Discovery Rate. 
 
Figure 7. Associations among disease activity, disordered genera and predicted pathways in the gut 
microbiota of SLE patients. A-C. Three genera, Streptococcus, Campylobacter, and Veillonella, were 
positively correlated with lupus activity. D-E. Two species, Streptococcus. anginosus, and Veillonella. 
dispar, were positively correlated with lupus activity. F. The genus Bifidobacterium was negatively 
related to lupus activity. G-I. The aberrant microbiome-associated pathways, Alanine aspartate and 
glutamate metabolism, Secondary bile acid biosynthesis and Lipid metabolism, had a positive 
association with the activity of SLE patients. It was analyzed by Spearman ranks tests, and the False 
Discovery Rate (FDR) q-value was then calculated for multiple testing. SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index; C3, Complement component 3.  
 
Figure 8. Receiver operating characteristic (ROC) curves demonstrating the performance of the genus 




among the healthy controls and RA patients based on the genus/species-level relative abundances using 
random forests. B. Prediction model of the gut microbiota to differentiate the active SLE patients from 
remissive SLE patients. AUC, Area under the curves of ROC; CI, Confidence Interval; SLE, Systemic 
lupus erythematosus patients; RA, Rheumatoid Arthritis patients.  
 
Supplemental materials 
Table S1: The comparison of α-diversity among different groups. 
SLE, Systemic lupus erythematosus patients; HC, healthy controls; RA, Rheumatoid Arthritis patients; 
A, the active SLE patients; R, the remissive SLE patients. The Wilcoxon rank sum test was used to 
determine significance in α-diversity. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Table S2: The comparisons of β-diversity among different medicine treatments in SLE patients. 
SLE, Systemic lupus erythematosus patients; Y= treated with specific drug; N= not treated. The 
ADONIS analysis was used to determine significance in β-diversity. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Table S3: The comparisons of β-diversity among different groups. 




A, the active SLE patients; R, the remissive SLE patients. The ADONIS analysis was used to determine 
significance in β-diversity. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Table S4: The comparisons of Firmicutes/Bacteroidetes ratio between different groups. 
F/B, Firmicutes/Bacteroidetes ratio; SLE, Systemic lupus erythematosus patients; HC, healthy controls; 
RA, Rheumatoid Arthritis patients; A, the active SLE patients; R, the remissive SLE patients. The 
Wilcoxon rank sum test was used to determine significance in α-diversity. *P < 0.05; **P < 0.01; ***P < 
0.001. 
 
Table S5: Association of disordered genera and aberrant microbiome-associated pathways with activity 
of SLE. 
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; C3, Complement component 3; CRP, 
C-reactive protein; ESR, Erythrocyte Sedimentation Rate; Anti-dsDNA, anti-double stranded DNA. 
They were analyzed by Spearman ranks tests, and False discovery rate (FDR) correction for multiple 
comparisons was employed. The FDR q-value was then calculated (r coefficient and FDR q-value were 
indicated for each parameter). *q < 0.05; **q< 0.01; ***q < 0.001. 
. 




patients from healthy controls and RA patients.  
 
Table S7: The importance of Genus and species in the random forests model to distinguish the active 
SLE patients from remissive SLE patients.  
 
Figure S1. Evaluation of sample preparation and sequencing quality. A. Chao1 dilution curve; B. 
Shannon dilution curve; C. OTU rank abundance. 
 
Figure S2. The associations among α-diversity and Hydroxychloroquine, Glucocorticoid, 
Cyclophosphamide and Biological agent in SLE patients.SLE, Systemic lupus erythematosus patients; 
Y= treated with specific drug; N= not treated. 
 
Figure S3. The Principal coordinate analysis (PCoA) of different medicine treatments. A-B. PCoA 
illustrating the grouping patterns of the Hydroxychloroquine-treated group (red) and 
Hydroxychloroquine-not treated group (blue) based on the weighted UniFrac distances (A) and 
unweighted UniFrac distances (B). C-D. PCoA illustrating the grouping patterns of the 
Glucocorticoid-treated group (red) and Glucocorticoid-not treated group (blue) based on the weighted 
UniFrac distances (C) and unweighted UniFrac distances (D). E-F. PCoA illustrating the grouping 




based on the weighted UniFrac distances (E) and unweighted UniFrac distances (F). G-H. PCoA 
illustrating the grouping patterns of the Biological agent-treated group (red) and Biological agent-not 
treated group (blue) based on the weighted UniFrac distances (G) and unweighted UniFrac distances (H). 
SLE, Systemic lupus erythematosus patients; Y= treated with specific drug; N= not treated. 
 
Figure S4. The Principal coordinate analysis (PCoA) of different groups.  A-B. PCoA illustrating the 
grouping patterns of the SLE patients and healthy controls based on the weighted UniFrac distances (A) 
and unweighted UniFrac distances (B). C-D. PCoA illustrating the grouping patterns of the SLE patients 
and RA patients based on the weighted UniFrac distances (C) and unweighted UniFrac distances (D). 
E-F. PCoA illustrating the grouping patterns of the active SLE patients and remissive SLE patients based 
on the weighted UniFrac distances (E) and unweighted UniFrac distances (F). SLE, Systemic lupus 






Figure S5. The differentially abundant taxa between SLE patient group and RA patient group. LEfSe 
analysis was performed to identify differentially abundant taxa, which are highlighted on the 
phylogenetic tree in cladogram format (A) and for which the LDA scores are shown (B). Green color 
indicates an increase taxa in SLE compared with RA, while the red color indicates an increase taxa in 
RA compared with SLE. For cladogram format, from the interior to the exterior, each layer represents 
the phylum, class, order, family, and genus level (significant taxa [p<0.05, Kruskal–Wallis test] with 
LDA score >2.5 were shown). SLE, Systemic lupus erythematosus patients; RA, Rheumatoid Arthritis 
patients.  
 
Figure S6. Receiver operating characteristic (ROC) curves demonstrating the performance of the 






























SLE, Systemic lupus erythematosus patients; HC, healthy controls; RA, Rheumatoid Arthritis patients; A, 
the active SLE patients; R, the remissive SLE patients. The Wilcoxon rank sum test was used to determine 
significance in α-diversity. *P < 0.05; **P < 0.01; ***P < 0.001. 

 SLE HC P-value 
Chao1 325.7 363.4 0.038* 
Observed species 269 314.5 0.004** 
Shannon index 5.043 5.202 0.089 
Simpson index 0.931 0.948 0.092 
 SLE RA P-value 
Chao1 325.7 288.5 0.326 
Observed species 269 216 0.324 
Shannon index 5.043 4.643 0.493 
Simpson index 0.931 0.920 0.629 
 A R P-value 
Chao1 351.7 303.1 0.123 
Observed species 300 251 0.092 
Shannon index 5.244 4.871 0.359 
Simpson index 0.931 0.924 0.663 
Table S2: The comparison of β-diversity among different medicine treatments in SLE 
patients. 
Group 澳  F. Modle R2 P-value 
 Hydroxychloroquine   
VS           
no Hydroxychloroquine 
weighted UniFrac 1.55 0.039 0.143 
Unweighted UniFrac 1.081 0.028 0.317 
   Glucocorticoid  
VS 
 no Hydroxychloroquine 
weighted UniFrac 0.657 0.017 0.647 
Unweighted UniFrac 1.3 0.033 0.129 
  Cyclophosphamide  
VS 
 no Cyclophosphamide 
weighted UniFrac 1.315 0.033 0.208 
Unweighted UniFrac 0.695 0.018 0.908 
  Biological agent 
 VS  
no Biological agent 
weighted UniFrac 0.155 0.004 0.996 
Unweighted UniFrac 0.857 0.022 0.672 
SLE, Systemic lupus erythematosus patients. The ADONIS analysis was used to determine 
significance in β-diversity.  
 
Table S3: The comparison of β-diversity among different groups. 
Group  F. Modle R2 P-value 
SLE - HC Unweighted UniFrac 3.406 0.054 0.000*** 
 Weighted UniFrac 1.705 0.028 0.132 
SLE - RA Unweighted UniFrac 1.271 0.021 0.143 
 Weighted UniFrac 0.993 0.017 0.399 
 A -R Unweighted UniFrac 1.549 0.039 0.047* 
 Weighted UniFrac 2.532 0.062 0.037* 
SLE, Systemic lupus erythematosus patients; HC, healthy controls; RA, Rheumatoid Arthritis patients; 
A, the active SLE patients; R, the remissive SLE patients. The ADONIS analysis was used to determine 
significance in β-diversity. *P < 0.05; **P < 0.01; ***P < 0.001. 

Table S4: The comparison of Firmicutes/Bacteroidetes ratio (F/B) between different groups. 
F/B 
 




A HC P-value 
3.907 2.661 0.549 
R HC P-value 
1.341 2.661 0.200 
F/B, Firmicutes/Bacteroidetes ratio; SLE, Systemic lupus erythematosus patients; HC, healthy controls; 
RA, Rheumatoid Arthritis patients; A, the active SLE patients; R, the remissive SLE patients. The 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S6: The importance of genus and species in the random forests model to 
distinguish the SLE patients from healthy controls and RA patients. 
 













100 100 rf group 
























































































































































































































































































NA.35 NA NA rf group 
Bacteria.Actinobacteria.Coriobacteriia.Coriobacteriales.Coriobact 39.8194 39.819 rf group 
eriaceae.Collinsella 3692 43692 








































































































































































































































































































NA.73 NA NA rf group 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Porphyromonad 29.4897 29.489 rf group 
aceae.Porphyromonas 9366 79366 








































































































































































































































































































NA.111 NA NA rf group 
Bacteria.Actinobacteria.Actinobacteria.Actinomycetales.Actinom 21.8661 21.866 rf group 
ycetaceae.Actinomyces 1256 11256 






























































































































































































































NA.140 NA NA rf group 
Bacteria.Bacteroidetes.Bacteroidia.Bacteroidales.Porphyromonad
aceae.Parabacteroides.gordonii 
0 0 rf group 
NA.141 NA NA rf group 
SLE, Systemic lupus erythematosus patients; HC, the healthy controls; RA, Rheumatoid 
Arthritis patients.  
 
Table S7: The importance of genus and species in the random forests model to 
distinguish the active SLE patients from remissive SLE patients. 







100 100 rf gro
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NA.27 NA NA rf gro
up 
Bacteria.Proteobacteria.Betaproteobacteria.Burkholderiales.Comam 33.117 33.117 rf gro
onadaceae.Comamonas 8873 8873 up 
























































































































































































































NA.49 NA NA rf gro
up 






























































































































































NA.66 NA NA rf gro
up 
Bacteria.Proteobacteria.Gammaproteobacteria.Cardiobacteriales.Car 22.832 22.832 rf gro
diobacteriaceae.Cardiobacterium 39661 39661 up 


































































































NA.76 NA NA rf gro
up 






















































































































































































































































































NA.105 NA NA rf gro
up 
Bacteria.Actinobacteria.Coriobacteriia.Coriobacteriales.Coriobacteri 15.439 15.439 rf gro
aceae.Collinsella.aerofaciens 21086 21086 up 








































































































































































































































































































































































A, the active SLE patients; R, the remissive SLE patients. 
